01 9Fampyra
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 103
2019 Revenue in Millions : 97
Growth (%) : 6
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 105
2020 Revenue in Millions : 103
Growth (%) : 2
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 97
2021 Revenue in Millions : 105
Growth (%) : -8
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 91
2022 Revenue in Millions : 97
Growth (%) : -6
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 80
2014 Revenue in Millions : 90
Growth (%) : 13%
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 93
2017 Revenue in Millions : 92
Growth (%) : 1%
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 92
2016 Revenue in Millions : 85
Growth (%) : 8
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 85
2015 Revenue in Millions : 90
Growth (%) : -6
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 97
2018 Revenue in Millions : 93
Growth (%) : 5
LOOKING FOR A SUPPLIER?